This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (previously presented) An antagonist of ghrelin, wherein the antagonist is a nucleic acid which specifically binds ghrelin, wherein said nucleic acid has the sequence of SEQ ID NO:8.

Claim 2 (canceled)

Claim 3 (currently amended) The antagonist according to claim 1 ~~or 2~~, wherein the nucleic acid comprises at least one L-nucleotide.

Claim 4 (currently amended) The antagonist according to claim 1 ~~or 2~~, wherein the antagonist is an L-nucleic acid.

Claim 5 (canceled)

Claim 6 (currently amended) ~~A nucleic acid~~ The antagonist according to claim 1, wherein said ghrelin is ~~which specifically binds~~ L-ghrelin~~, wherein said nucleic acid has the sequence of SEQ ID NO:8~~.

Claims 7-10 (canceled)

Claim 11 (previously presented) The nucleic acid of claim 6, wherein the nucleic acid is selected from the group consisting of DNA, RNA and combinations thereof.

Claims 12-15 (canceled)

Claim 16 (currently amended) A method for making the nucleic acid of claim 1 ~~6~~, comprising the steps:

a) generating a heterogeneous population of nucleic acids;

b) contacting the population of step a) with a ghrelin;

c) separating the nucleic acid(s) not interacting with the ghrelin to obtain the nucleic acid of claim 1;

d) optionally separating the nucleic acid(s) interacting with the ghrelin; and

e) optionally sequencing the nucleic acid(s) interacting with the ghrelin.

Claim 17 (currently amended) The method according to claim 16, further comprising amplification of the nucleic acid(s) interacting with the ghrelin.

Claim 18 (original) The method according to claim 16 or 17, wherein steps b) to d) are repeated.

Claim 19 (canceled)

Claim 20 (currently amended) A method for making the L-nucleic acid of claim 4 ~~6~~ comprising the following steps:

a) generating a heterogeneous population of D-nucleic acids;

b) contacting the population of step a) with D-ghrelin;

c) separating the D-nucleic acid not interacting with D-ghrelin;

d) sequencing the D-nucleic acid interacting with D-ghrelin; and

e) synthesizing the L-nucleic acid sequence~~(s) which is/are~~ identical to the sequence of the D-nucleic acid~~(s)~~ obtained in step d) to obtain the nucleic acid of claim 4.

Claim 21 (previously presented) The method according to claim 20 further comprising amplifying the D-nucleic acid interacting with D-ghrelin.

Claim 22 (previously presented) The method according to claim 20 or 21, characterized in that steps b) to e) are repeated.

Claim 23 (canceled)

Claim 24 (currently amended) A method of treating a disorder ~~comprising~~ requiring reducing ghrelin or GHSR1a function, comprising the step of administering to a patient in need of treatment the ~~nucleic acid of claim 6, or the~~ antagonist of claim 1 ~~or 2~~.

Claim 25 (previously presented) The method of claim 24 wherein the disorder is selected from the group consisting of obesity; improper regulation of energy balance; improper appetite or body weight; eating disorders; diabetes; improper glucose metabolism; tumour; improper blood pressure and cardiovascular disease.

Claim 26 (currently amended) A composition comprising ~~the nucleic acid of claim 6 or~~ the antagonist of claim 1 ~~or 2~~, and a pharmaceutical acceptable carrier.

Claim 27 (currently amended) A complex comprising ghrelin and the nucleic acid of claim 1 ~~6~~.

Claim 28 (canceled)

Claim 29 (currently amended) A method for screening for a ghrelin antagonist comprising the steps:

a) providing a candidate ghrelin antagonist,

b) providing ~~the nucleic acid according to claim 6, or~~ the antagonist according to claim 1 ~~or 2~~,

c) providing a test system providing a signal in the presence of a ghrelin antagonist, wherein a reagent is labeled, and

d) determining whether the candidate ghrelin antagonist is a ghrelin antagonist.

Claim 30 (currently amended) A kit comprising ~~the nucleic acid of claim 6, or~~ the antagonist of claim 1 ~~or 2~~.

Claims 31-44 (canceled)

Claim 45 (previously presented) The complex of claim 27, wherein said complex is crystalline.

Claims 46-49 (canceled)